Japan · Delayed Price · Currency is JPY Teijin Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw a decline in revenue and adjusted operating income, mainly due to business divestments and impairment losses, resulting in a net loss. The full-year outlook remains unchanged, with ongoing structural reforms and a focus on healthcare and fibers for future growth.
-
Q2 FY2025 saw revenue and adjusted operating income decline year-over-year, mainly due to weakness in materials and aramid, while healthcare improved. FY2025 guidance was lowered, but the annual dividend is maintained. Cost reforms and restructuring are ongoing.
Fiscal Year 2025
-
Customer-centric strategy leverages expertise in fibers, healthcare, and resin, focusing on high-value products and circular economy. Divestments and acquisitions sharpen core business, while new technologies and regional adaptation drive future growth.
-
Fiscal 2024 saw profit growth, improved ROE, and strong Materials and Fibers & Products Converting performance. Fiscal 2025 is expected to bring higher adjusted operating income despite lower revenue from business divestitures, with continued focus on structural reforms and stable dividends.
-
Healthcare segment targets sustainable growth by leveraging its home care leadership, expanding into rare diseases, and integrating pharmaceuticals and devices, while mitigating pharma revenue risks from generics and price cuts.